II. Amendments to the Claims

In compliance with the Revised Amendment Format, the text of all claims under examination is submitted, and the status of each is identified. This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. (Currently amended) A method for treating a viral infection in a warm-blooded animal comprising administering to the warm-blooded animal a therapeutically effective amount of a compound of the following formula:



wherein,

R_1 is $-COOR_3$ or $-CONHR_3$;

when R_1 is $-COOR_3$,

R_3 is haloalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkalkyl, heterocycloalkyl, heterocycloalkalkyl, substituted or unsubstituted benzyl, hydroxyalkyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl;

when R_1 is $-CONHR_3$,

R_3 is ~~alkyl,~~ haloalkyl, ~~alkenyl,~~ haloalkenyl, ~~cycloalkyl, cycloalkalkyl,~~ heterocycloalkyl, heterocycloalkalkyl, ~~substituted or unsubstituted benzyl,~~ hydroxyalkyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl; and

each of X and Y is independently hydrogen, alkyl, alkenyl, cycloalkyl, haloalkyl, haloalkenyl, halogen, nitro, or amino;

a pharmaceutically acceptable salt thereof or a prodrug thereof.

2. (Originally filed) A method according to claim 1 wherein said compound is in the form of a pharmaceutically acceptable salt thereof.

3. (Originally filed) A method according to claim 2 wherein said pharmaceutically acceptable salt is a hydrochloride salt.

4. (Originally filed) A method according to claim 1 wherein said compound is in the form of a prodrug thereof.

5. (Originally filed) A method according to claim 1 wherein said compound is of the following formula

A-3:



A-3 .

6. (Originally filed) A method according to claim 5 wherein Y is hydrogen or chloro, and R_3 is selected from the group consisting of alkyl, alkenyl, oligo(alkoxy)alkyl, and substituted or unsubstituted benzyl.

7. (Originally filed) A method according to claim 1 wherein said compound is of the following formula

A-4:



A-4 .

8. (Currently amended) A method according to claim 7 wherein Y is hydrogen or chloro~~, and R_3 is selected from the group consisting of alkyl, alkenyl, oligo(alkoxy)alkyl, and substituted or unsubstituted benzyl~~.

9. (Originally filed) A method according to claim 1 wherein said compound is micronized and is suitable for administering to said warm-blooded animal by injection.

10. (Originally filed) A method according to claim 1 wherein said compound is administered in an amount of from 10 mg/kg body weight to 10,000 mg/kg body weight.

11. (Originally filed) A method according to claim 1 wherein said compound is administered orally, enterically, intravenously, peritoneally, or by injection.

12. (Originally filed) A method according to claim 1 wherein said compound is administered in a pharmaceutically acceptable carrier.

13. (Originally filed) A method according to Claim 1 wherein said compound is coupled to a soluble polymer.

14. (Originally filed) A method according to Claim 1 wherein said compound is coupled to a biodegradable polymer.

15. (Originally filed) A method according to Claim 1 wherein the viral infection is due to an RNA virus.

16. (Originally filed) The method according to Claim 15 wherein the RNA virus is a human immunodeficiency virus.